Targeted antimicrobial peptides

Frontiers in Immunology

Volumn 3, Issue OCT, 2012, Pages

  Devocelle, Marc ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874221218     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00309     Document Type: Article

References (37)

1. Arnusch, C. J., Pieters, R. J., and Breukink, E. (2012). Enhanced membrane pore formation through high-affnity targeted antimicrobial peptides. PLoS ONE 7, e39768. doi: 10.1371/journal.pone.0039768
2. Bray, L. B. (2003). Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2, 587-593.
3. Brogden, N. K., and Brogden, K. A. (2011). Wil l new generations of modifed antimicrobial peptides improve their potential as pharmaceuticals? Int. J. Antimicrob. Agents 38, 217- 225.
4. Brown, K. L., Cosseau, C., Gardy, J. L., and Hancock, R. E. W. (2007). Complexities of targeting innate immunity to treat infection. Trends Immunol. 28, 260-266.
5. Chen, X., Zhang, M., Zhou, C., Kallenbach, N. R., and Ren, D. (2011). Control of bacterial persister cells by trp/ arg-containing antimicrobial peptides. Appl. Environ. Microbiol. 77, 4878-4885.
6. Desgranges, S., Le Prieult, F., Daly, A., Lydon, J., Brennan, M., Rai, D. K., et al. (2011). In vitro activities against cystic fbrosis pathogens of synthetic host defence pro-peptides processed by neutrophil elastase. Antimicrob. Agents Chemother. 55, 2487-2489.
7. Desgranges, S., Ruddle, C. C., Burke, L. P., McFadden, T. M., O'Brien, J. E., Fitzgerald-Hughes, D., et al. (2012). β-Lactam-host defence peptide conjugates as antibiotic prodrug candidates targeting resistant bacteria. RSC Adv. 2, 2480-2492.
8. Eckert, R., He, J., Yarbrough, D. K., Qi, F., Anderson, M. H., and Shi, W. (2006). Targeted killing of Streptococcus mutans by a pheromone-guided "Smart" antimicrobial peptide. Antimicrob. Agents Chemother. 50, 3651-3657.
9. Finlay, B. B., and Hancock, R. E. W. (2004). Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. 2, 497-504.
10. Fjell, C. D., Hiss, J. A., Hancock, R. E. W., and Schneider, G. (2012). Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11, 37-51.
11. Franzman, M. R., Burnell, K. K., Dehkordi-Vakil, F. H., Guthmiller, J. M., Dawson, D. V., and Brogden, K. A. (2009). Targeted antimicrobial activity of a specifc IgG-SMAP28 conjugate against Porphyromonas gin-givalis in a mixed culture. Int. J. Antimicrob. Agents 33, 14-20.
12. Giacometti, A., Cirioni, O., Del Prete, M. S., Barchiesi, F., Fortuna, M., Drenaggi, D., et al. (2000). In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 44, 1716-1719.
13. Hancock, R. E., Nijnik, A., and Philpott, D. J. (2012). Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol. 10, 243-254.
14. Hancock, R. E. W. (2001). Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1, 156-164.
15. Hancock, R. E. W., and Sahl, H.-G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551-1557.
16. Harris, J. M., and Chess, R. B. (2003). Effect of pegyla-tion on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221.
17. Imura, Y., Nishida, M., and Matsuzaki, K. (2007). Action mechanism of PEGylated magainin 2 analogue pep-tide. Biochim. Biophys. Acta 1768, 2578-2585.
18. Kennedy, D. A., Vembu, N., Fronczek, F. R., and Devocelle, M. (2011). Synthesis of mutual azo prodrugs of anti-infammatory agents and peptides facilitated by α-aminoisobutyric acid. J. Org. Chem. 76, 9641-9647.
19. Lehrer, R. I. (2004). "Overview: antimicrobial peptides, as seen from a rearview mirror," in Mammalian Host Defense Peptides, eds D. A. Devine and R. E. W. Hancock (Cambridge: Cambridge University Press), 5-8.
20. Li, L., He, J., Eckert, R., Yarbrough, D., Lux, R., Anderson, M., et al. (2010). Design and characterization of an acid-activated antimicrobial peptide. Chem. Biol. Drug Des. 75, 127-132.
21. Li, Y. (2011). Recombinant production of antimicrobial peptides in Escherichia coli: a review. Protein Expr. Purif. 80, 260-267.
22. Mader, J. S., and Hoskin, D. W. (2006). Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin. Investig. Drugs 15, 933-946.
23. McClanahan, J. R., Peyyala, R., Mahajan, R., Montelaro, R. C., Novak, K. F., and Puleo, D. A. (2011). Bioactivity of WLBU2 peptide antibiotic in combination with bioerodible polymer. Int. J. Antimicrob. Agents 38, 530-533.
24. Mygind, P. H., Fischer, R. L., Schnorr, K. M., Hansen, M. T., Sönksen, C. P., Ludvigsen, S., et al. (2005). Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975-980.
25. Papo, N., and Shai, Y. (2005). Host defense peptides as new weapons in cancer treatment. Cell. Mol. Life Sci. 62, 784-790.
26. Pauletti, G. M., Gangwar, S., Siahaan, T. J., Aubé, J., and Borchardt, R. T. (1997). Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies. Ad v. D r u g D e liv. Re v. 27, 235-256.
27. Peschel, A., and Sahl, H.-G. (2006). The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4, 529-536.
28. Peschen, D., Li, H.-P., Fischer, R., Kreuzaler, F., and Liao, Y.-C. (2004). Fusion proteins comprising a Fusarium-specifc antibody linked to antifungal peptides protect plants against a fungal pathogen. Nat. Biotechnol. 22, 732-738.
29. Pokrovskaya, V., and Baasov, T. (2010). Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin. Drug Discov. 5, 883-902.
30. Qiu, X.-Q., Wang, H., Lu, X.-F., Zhang, J., Li, S.-F., Cheng, G., et al. (2003). An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat. Biotechnol. 21, 1480-1485.
31. Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., et al. (2008). Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7, 255-270.
32. Stella, V. J. (2004). Prodrugs as therapeutics. Expert Opin. Ther. Patents 14, 277-280.
33. Szynol, A., de Haard, J. J. W., Veerman, E. C., de Soet, J. J., and van Nieuw Amerongen, A. V. (2006). Design of a peptibody consisting of the antimicrobial peptide dhvar5 and a llama variable heavy-chain antibody fragment. Chem. Biol. Drug Des. 67, 425-431.
34. Urbán, P., Valle-Delgado, J. J., Moles, E., Marques, J., Díez, C., and Fernàndez-Busquets, X. (2012). Nanotools for the delivery of antimicrobial peptides. Curr. Drug Targets 13, 1158-1172.
35. Yeaman, M. R., and Yount, N. Y. (2007). Unifying themes in host defence effector polypeptides. Nat. Rev. Microbiol. 5, 727-740.
36. Yount, N. Y., and Yeaman, M. R. (2012). Emerging themesand therapeutic prospects for anti-infective peptides. Annu. Rev. Pharmacol. Toxicol. 52, 337-360.
37. Zasloff, M. (2002). Antimicrobial peptides of multicel-lular organisms. Nature 415, 389-395.